2014
DOI: 10.1111/vec.12208
|View full text |Cite
|
Sign up to set email alerts
|

Hydroxyethyl starch: A review of pharmacokinetics, pharmacodynamics, current products, and potential clinical risks, benefits, and use

Abstract: The extrapolation of data from human studies directly to small animals should be done with the knowledge that there may be species variations and different pharmacokinetics with different HES solutions. Veterinary reports indicate that bolus and continuous rate infusions of 6% hetastarch solutions at moderate doses are well tolerated in feline and canine subjects. Further research in domesticated species is necessary to better define and expand the knowledge regarding use of HES solutions in small animal medic… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
107
0

Year Published

2016
2016
2021
2021

Publication Types

Select...
5
4

Relationship

0
9

Authors

Journals

citations
Cited by 69 publications
(107 citation statements)
references
References 194 publications
(427 reference statements)
0
107
0
Order By: Relevance
“…Previous guidelines for the use of HES in small animals have largely been based on human literature and authors’ personal experiences . Adopting the new recommendations for people and restricting the use of HES in critically ill veterinary patients would therefore be consistent with previous practice.…”
Section: Introductionmentioning
confidence: 97%
“…Previous guidelines for the use of HES in small animals have largely been based on human literature and authors’ personal experiences . Adopting the new recommendations for people and restricting the use of HES in critically ill veterinary patients would therefore be consistent with previous practice.…”
Section: Introductionmentioning
confidence: 97%
“…In human beings, a plasma terminal half‐life of 12.1 hours has been reported for 6% tetrastarch 130/0.4 . Dogs are reported to have higher plasma concentrations of α‐amylase, the enzyme responsible for breakdown of synthetic starch products, than human beings, which may be why elimination half‐life of some hetastarch products is shorter in dogs than people . Further evaluation of the pharmacokinetics of tetrastarch products in dogs is required to establish elimination half‐life to ensure that appropriate washout periods are employed.…”
Section: Discussionmentioning
confidence: 99%
“…Additionally, these solutions may impact coagulation and platelet function. Dogs that receive >25% of their blood volume as HES can experience significant bleeding . In this case, the dog received 60 mL/kg of HES.…”
Section: Discussionmentioning
confidence: 99%